Anixa Biosciences

Anixa is a biotechnology company that is developing programs for addressing cancer and infectious disease. The therapeutics portfolio of Anixa includes a cancer immunotherapy program that uses a novel type of CAR-T, referred to as the chimeric endocrine receptor T-cell (CER-T) technology, and a COVID-19 therapeutics program that focuses on inhibiting certain viral protein function.

The vaccine portfolio of Anixa comprises of technology that focuses on the immunization against certain retired proteins that are associated with breast cancer, specifically triple negative breast cancer and the ovarian cancer. Retired proteins are proteins that are expressed at particular times in life and are no longer expressed in healthy people.

Anixa continues to examine and study evolving technologies in complementary fields for more development and commercialization.